MedWell Ai Reports Strong Q2 Revenues Of $548,315 And Provides Guidance For Full Year 2025 Exceeding $2,200,000

Rhea-AI Summary

MedWell Ai (OTCQB:MWAI) reported Q2 FY2025 revenue of $548,315 and provided full‑year 2025 guidance exceeding $2,200,000. Revenues rose ~280% YoY for the quarter and ~700% for six months. Net loss, operating expenses and liabilities were materially reduced versus prior periods.

Key metrics: Q2 revenue $548,315; six‑month revenue $1,075,806; Q2 net loss $266,221; total liabilities/deficit $468,655.

Positive

• Revenue +280% year-over-year for Q2
• Six‑month revenue +700% year-over-year
• Net loss reduced to $266,221 in Q2
• Guidance exceeding $2,200,000 for full year 2025

Negative

• Company remains net loss of $266,221 for Q2
• General and administrative expenses still $388,509 in Q2
• Total liabilities/stockholders deficit $468,655 remains

News Market Reaction – MWAI

+2.33%

1 alert

+2.33% News Effect

On the day this news was published, MWAI gained 2.33%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CLEARWATER, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- MedWell Ai, Inc, (OTCQB:MWAI) ("Company") is a portfolio company, specializing in AI-driven solutions for B2B markets in pharmaceuticals, healthcare, and wellness, is pleased to confirm the filing, after the market close, of its Quarterly Report (Form 10-Q), for the financial period, ending on December 31, 2025.

The Company reported $548,315 in Revenue for its fiscal second quarter of 2025. This performance was result of a successful strategic shift toward building an AI-driven healthcare, pharmaceutical and biological wellness portfolio. 

Key Financial Highlights:

Increased Total Revenues:

• For three months, ended December 31, 2025, Company had generated total revenues of 548,315 vs $142,861 for three months, ended December 31, 2024 (280%+ increase).
• For six months, ended December 31, 2025, Company had generated total revenues of $1,075,806 vs $144,009 for six months, ended December, 2024 (700%+ increase).

Reduced Total Loss From Operations:

• For three months, ended December 31, 2025, Company's net loss was reduced to $266,221 vs $315,096 for three months, ended December 31, 2024.
• For six months, ended December 31, 2025, Company's net loss was reduced to $592,255 vs $904,080 for six months, ended December 31, 2024.

Reduced General And Administrative Expenses:

• For three months, ended December 31, 2025, Company's expenses were reduced to $388,509 vs $625,199 for three months, ended December 31, 2024.
• For six months, ended December 31, 2025, Company's expenses were reduced to $796,839 vs $960,413 for six months, ended December 31, 2024.

Reduced Net Loss Per Common Share:

• For three months, ended December 31, 2025, Company's net loss was reduced to 0.045 cents vs 0.062 cents for three months, ended December 31, 2024.
• For six months, ended December 31, 2025, Company's net loss was reduced to 0.138 cents vs 0.174 cents for six months, ended December 31, 2024. 

Total Liabilities/Mezzanine/Stockholder's Deficit:  For three months, ended December 31, 2025, Company's liabilities deficit was reduced to $468,655 from $805,500, for three months, ended June 30, 2025.

Steve Rubakh, CEO of MedWell Ai, Inc, comments:

"MWAI is a newly formed entity (formerly Integrated Ventures, Inc) is operating in AI-driven pharma/healthcare/wellness category. Q2 financial results reflect significant top-line progress for fast growing small cap company, driven by its B2B pharma procurement arm, MedWell USA, which focuses on high-demand in-office use, wellness products, like compounded GLP-1 agonists for weight management.

The current revenue ramp up suggests a successful scaling process in the competitive but rapidly growing regenerative wellness and telemedicine space. This aligns with recent trends in longevity, personalized medicine and corporate wellness markets.

Please visit our corporate websites for additional information: ( 1) Corporate:  www.medwellai.com, (2) Pharma Procurement/E-Portal: www.medwellusa.com and (3) 24/7 Telemedicine: www.telemd.ai launching soon)."

Safe Harbor Statement:

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.

 InvestorWire Service Contact:

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

FAQ

What did MedWell Ai (MWAI) report for Q2 FY2025 revenue on February 23, 2026?

MedWell Ai reported Q2 FY2025 revenue of $548,315, a ~280% increase versus prior year. According to the company, this rise reflects a strategic shift into AI-driven pharma and B2B wellness services and growth from its MedWell USA procurement arm.

How much revenue did MedWell Ai (MWAI) generate for the first six months of fiscal 2025?

MedWell Ai reported $1,075,806 in revenue for the six months ended December 31, 2025. According to the company, that represents an increase of roughly 700% compared with the same six-month period in fiscal 2024.

What guidance did MedWell Ai (MWAI) provide for full year 2025 on February 23, 2026?

MedWell Ai provided full‑year 2025 guidance exceeding $2,200,000. According to the company, this outlook follows the current revenue ramp from its B2B pharma procurement and wellness offerings.

Did MedWell Ai (MWAI) improve profitability metrics in Q2 FY2025?

Yes. Net loss narrowed to $266,221 for Q2 FY2025 from $315,096 a year earlier. According to the company, operating losses and G&A expenses were reduced compared with prior periods.

What changes occurred to MedWell Ai's (MWAI) expenses and liabilities in Q2 FY2025?

General and administrative expenses declined to $388,509 in Q2 and total liabilities/deficit fell to $468,655. According to the company, cost reductions accompanied its revenue growth and strategic shift.

How might MedWell Ai's (MWAI) Q2 results affect investors evaluating the company?

Q2 shows strong top-line growth but continued net losses, indicating improving momentum with remaining risk. According to the company, revenue increases and reduced losses suggest progress while cash and liabilities remain important investor considerations.